RhumbLine Advisers
OKUR

RhumbLine Advisers’s OnKure Therapeutics OKUR Stock Holding History

RhumbLine Advisers’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-98
Closed -$1.48K – 4348
2024
Q2 		$1.48K Sell
98
-999
-91% -$16.9K ﹤0.01% 4207
2024
Q1 		$18.2K Buy
1,097
+38
+4% +$627 ﹤0.01% 3775
2023
Q4 		$16.9K Sell
1,059
-74
-7% -$4.61K ﹤0.01% 3794
2023
Q3 		$86.3K Buy
1,133
+323
+40% +$22K ﹤0.01% 3506
2023
Q2 		$53.2K Buy
+810
New +$65.3K ﹤0.01% 3667

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RhumbLine Advisers's OKUR Position: Q3 2024 in Review

RhumbLine Advisers sold out of OnKure Therapeutics (OKUR) in Q3 2024, closing a stake of 98 shares — an estimated $1.48K sold.

RhumbLine Advisers first reported a position in OKUR in Q2 2023 and held it in 5 quarters. The position peaked at $86.3K in Q3 2023. 51 funds tracked by Wall St. Rank hold OKUR as of Q3 2024.

  • RhumbLine Advisers reported no remaining OnKure Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 98 OnKure Therapeutics shares in Q3 2024, an estimated $1.48K.
  • RhumbLine Advisers first reported a position in OnKure Therapeutics in Q2 2023 and held it in 5 quarters.
  • RhumbLine Advisers's OnKure Therapeutics position peaked at $86.3K in Q3 2023.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.